AKT1 and neoplasm: An oral dose of 3–5 mg/kg withaferin A attenuated the activation of Akt and stimulated Forkhead Box-O3a (FOXO3a)-mediated prostate apoptotic response-4 (Par-4) activation, effectively inhibiting the tumor progression in prostate cancer cells [96,97,98].